Liquid Biopsy and Other Non-Invasive Cancer Diagnostics Market by 2030

Nearly 300 non-invasive diagnostic tests, designed for the detection of various types of cancers, are either already available in the market or under development across the world

Given the invasive and cost-intensive nature of tissue biopsies, there is a significant unmet need for safer and more patient-friendly cancer diagnostics that are capable of offering highly accurate, and actionable insights related to the disease.

Liquid Biopsy and Other Non-Invasive Cancer Diagnostics Market, Forecast to 2030

The financial opportunity within the liquid biopsy and other non-invasive cancer diagnostics market has been analyzed across the following segments:

Type of Tumor Marker

• ctDNA
• cfDNA
• CTCs
• Exosomes
• Others

Application

• Diagnosis / Early Diagnosis
• Patient Monitoring
• Recurrence Monitoring

Target Cancer Indication

• Breast Cancer
• Lung Cancer
• Colorectal Cancer
• Prostate Cancer
• Bladder Cancer
• Melanoma
• Gastric Cancer
• Pancreatic Cancer
• Ovarian Cancer
• Others

End Users

• Hospitals
• Research Institutes
• Others

Key Geographical Regions

• North America
• Europe
• Asia-Pacific
• Rest of the World

Get Latest Market Insights:

Liquid Biopsy and Other Non-Invasive Cancer Diagnostics Market is estimated to be worth around USD 20.1 billion by 2030

The Liquid Biopsy and Other Non-Invasive Cancer Diagnostics Market (3rd Edition), 2019-2030: Focus on Circulating Tumor Markers such as CTCs, ctDNA, cfDNA, Exosomes and Other Biomarkers report features the following companies, which we identified to be key players in this domain:

Key Players:

• Amoy Diagnostics
• DiaCarta
• HaploX Biotechnology
• NeoGenomics
• QIAGEN
• Swift Biosciences
• Sysmex Inostics
• Thermo Fisher Scientific

Table of Contents

1. Preface

2. Executive Summary

3. Introduction

4. Non-Invasive Cancer Screening and Diagnosis

5. Market Landscape

6. Company Profiles

7. Partnerships and Collaborations

8. Funding and Investment Analysis

9. Liquid Biopsy: Initiatives of Big Pharma Players

10. Key Acquisition Targets

11. Other Non-Invasive Cancer Diagnostics

12. Market Sizing and Opportunity Analysis

13. Survey Insights

14. Conclusion

15. Executive Insights

16. Appendix 1: Tabulated Data

17. Appendix 2: List of Companies and Organizations

Request for Customization: https://www.rootsanalysis.com/reports/279/request-customization.html

About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com

Contact Information

Roots Analysis Private Limited

Gaurav Chaudhary

+1 (415) 800 3415

Gaurav.Chaudhary@rootsanalysis.com

Also Visit Our Latest Publication:

Cloud-based Solutions for Drug Discovery, Development and Manufacturing Market

CAR-T Cell Therapies Market

Patient Recruitment and Retention Services Market

mRNA Therapeutics and Vaccines Market

T-Cell (CAR-T, TCR, and TIL) Therapies Market

Article source: https://article-realm.com/article/Finance/11760-Liquid-Biopsy-and-Other-Non-Invasive-Cancer-Diagnostics-Market-by-2030.html